4//SEC Filing
ALLERGAN INC 4
Accession 0001127602-15-012120
CIK 0000850693operating
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 7:24 PM ET
Size
30.9 KB
Accession
0001127602-15-012120
Insider Transaction Report
Form 4
ALLERGAN INCAGN
Whitcup Scott M
Executive VP, R&D, CSO
Transactions
- Gift
Common Stock
2015-02-20−9,766→ 7,409 total - Disposition to Issuer
Common Stock
2015-03-17−18,682.669→ 0 total - Disposition to Issuer
Common Stock
2015-03-17−1,709.707→ 0 total(indirect: By 401(k)) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−105,500→ 0 totalExercise: $64.47Exp: 2018-02-14→ Common Stock (105,500 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−92,600→ 0 totalExercise: $59.13Exp: 2020-02-22→ Common Stock (92,600 underlying) - Award
Common Stock
2015-03-17+11,273.669→ 18,682.669 total - Disposition to Issuer
Common Stock
2015-03-17−1,739.106→ 0 total(indirect: By Esop) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−89,200→ 0 totalExercise: $58.55Exp: 2017-02-02→ Common Stock (89,200 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−130,400→ 0 totalExercise: $40.16Exp: 2019-02-20→ Common Stock (130,400 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−120,000→ 0 totalExercise: $75.58Exp: 2021-02-17→ Common Stock (120,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−60,000→ 0 totalExercise: $105.87Exp: 2023-02-21→ Common Stock (60,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−25,000→ 0 totalExercise: $87.91Exp: 2022-02-17→ Common Stock (25,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−58,815→ 0 totalExercise: $125.07Exp: 2024-02-21→ Common Stock (58,815 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−67,000→ 0 totalExercise: $87.91Exp: 2022-02-17→ Common Stock (67,000 underlying)
Footnotes (4)
- [F1]Represents 11,271 performance-based restricted stock units granted on October 29, 2014 and 2.6690 dividend equivalent rights acquired with respect to each vested restricted stock unit (collectively, the "RSUs"). The RSUs vested in full on the Effective Date pursuant to the terms of the Merger Agreement (each as defined below).
- [F2]Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis) and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for $129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of $307.51 per share on the Effective Date.
- [F3]The option was previously reported as covering 44,600 shares at an exercise price of $117.10. The Issuer effected a two-for-one stock split on June 22, 2007, which resulted in 89,200 shares held by the reporting person at an exercise price of $58.55.
- [F4]Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times $294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus $129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.
Documents
Issuer
ALLERGAN INC
CIK 0000850693
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000850693
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 7:24 PM ET
- Size
- 30.9 KB